Elevance Health, Inc. insider trading
ELVfinancial statementsForm 4 filings on EDGAR119 transactions since Nov 1, 2024
From August 4, 2026 to November 1, 2026, 0 insiders at Elevance Health, Inc. bought $0 of stock in the open market, and 1 sold $5M. Officers and directors accounted for $0 of purchases and $5M of sales. The last reported transaction was an open-market sale by Kaye Mark on October 22, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through October 23, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $5MAug 4, 2026 – Nov 1, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Oct 30, 2026. Insider data through Nov 1, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
119 transactions from November 1, 2024 to November 1, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Oct 22, 2026 | Kaye Mark | EVP & CFO | open-market sale | 400 | $434.00 | $174K | 30,103 | Oct 23, 2026 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | open-market sale | 321 | $435.25 | $140K | 29,782 | Oct 23, 2026 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | open-market sale | 1,660 | $436.20 | $724K | 28,122 | Oct 23, 2026 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | open-market sale | 560 | $437.07 | $245K | 27,562 | Oct 23, 2026 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | open-market sale | 240 | $438.22 | $105K | 27,322 | Oct 23, 2026 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | open-market sale | 1,160 | $439.25 | $510K | 26,162 | Oct 23, 2026 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | open-market sale | 1,720 | $440.44 | $758K | 24,442 | Oct 23, 2026 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | open-market sale | 2,343 | $441.34 | $1M | 22,099 | Oct 23, 2026 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | open-market sale | 480 | $442.61 | $212K | 21,619 | Oct 23, 2026 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | open-market sale | 440 | $443.81 | $195K | 21,179 | Oct 23, 2026 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | open-market sale | 160 | $444.85 | $71K | 21,019 | Oct 23, 2026 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | open-market sale | 827 | $446.05 | $369K | 20,192 | Oct 23, 2026 |
| Oct 22, 2026 | Kaye Mark | EVP & CFO | open-market sale | 273 | $447.19 | $122K | 19,919 | Oct 23, 2026 |
| Oct 2, 2026 | Kaye Mark | EVP & CFO | tax withholding | 4,161 | $386.43 | $2M | 27,876 | Oct 6, 2026 |
| Oct 2, 2026 | Kaye Mark | EVP & CFO | award | 2,627 | $0.00 | — | 30,503 | Oct 6, 2026 |
| Sep 3, 2026 | Wessling Erin M | EVP & Chief Legal Officer | tax withholding | 255 | $414.78 | $106K | 7,230 | Sep 4, 2026 |
| Sep 2, 2026 | Wessling Erin M | EVP & Chief Legal Officer | tax withholding | 94 | $405.84 | $38K | 7,485 | Sep 4, 2026 |
| Sep 2, 2026 | Craig Ryan R | EVP & Chief HR Officer | tax withholding | 144 | $405.84 | $58K | 6,530 | Sep 4, 2026 |
| Jul 17, 2026 | Peru Ramiro G | Director | open-market buy | 1,000 | $366.05 | $366K | 10,908 | Jul 17, 2026 |
| Jul 17, 2026 | Boudreaux Gail | President and CEO, Director | open-market buy | 680 | $366.41 | $249K | 169,931 | Jul 17, 2026 |
| Jul 17, 2026 | Boudreaux Gail | President and CEO, Director | open-market buy | 2,045 | $368.25 | $753K | 171,976 | Jul 17, 2026 |
| Jun 12, 2026 | Penczek Ronald W | CAO & Controller | open-market sale | 369 | $403.16 | $149K | 3,740 | Jun 15, 2026 |
| Jun 11, 2026 | Dixon Robert L JR | Director | open-market sale | 151 | $401.77 | $61K | 10,734 | Jun 12, 2026 |
| May 19, 2026 | Penczek Ronald W | CAO & Controller | option exercise | 654 | $271.27 | $177K | 4,763 | May 20, 2026 |
| May 19, 2026 | Penczek Ronald W | CAO & Controller | option exercise | 877 | $311.48 | $273K | 5,640 | May 20, 2026 |
| May 19, 2026 | Penczek Ronald W | CAO & Controller | open-market sale | 1,531 | $403.13 | $617K | 4,109 | May 20, 2026 |
| May 13, 2026 | Strable-Soethout Deanna D | Director | award | 563 | $0.00 | — | 2,209 | May 15, 2026 |
| May 13, 2026 | Schulman Amy W | Director | award | 563 | $0.00 | — | 781 | May 15, 2026 |
| May 13, 2026 | Schneider Ryan M. | Director | award | 563 | $0.00 | — | 7,163 | May 15, 2026 |
| May 13, 2026 | Peru Ramiro G | Director | award | 563 | $0.00 | — | 9,908 | May 15, 2026 |
| May 13, 2026 | Neri Antonio F | Director | award | 563 | $0.00 | — | 5,488 | May 15, 2026 |
| May 13, 2026 | Jallal Bahija | Director | award | 563 | $0.00 | — | 5,351 | May 15, 2026 |
| May 13, 2026 | Hay Lewis III | Director | award | 563 | $0.00 | — | 12,070 | May 15, 2026 |
| May 13, 2026 | Dixon Robert L JR | Director | award | 563 | $0.00 | — | 10,885 | May 15, 2026 |
| May 13, 2026 | DeVore Susan D. | Director | award | 563 | $0.00 | — | 4,065 | May 15, 2026 |
| May 13, 2026 | Collis Steven H | Director | award | 563 | $0.00 | — | 4,202 | May 15, 2026 |
| Mar 12, 2026 | Schulman Amy W | Director | open-market sale | 26 | $287.50 | $7K | 218 | Mar 23, 2026 |
| Mar 6, 2026 | Kendrick Charles Morgan JR | EVP & President, Commercial | open-market sale | 3,196 | $284.92 | $911K | 11,791 | Mar 9, 2026 |
| Mar 5, 2026 | Collis Steven H | Director | open-market buy | 3,000 | $289.84 | $870K | 3,639 | Mar 6, 2026 |
| Mar 3, 2026 | Penczek Ronald W | CAO & Controller | tax withholding | 37 | $284.03 | $11K | 4,099 | Mar 4, 2026 |
| Mar 3, 2026 | Wessling Erin M | EVP & Chief Legal Officer | tax withholding | 417 | $284.03 | $118K | 7,579 | Mar 4, 2026 |
| Mar 3, 2026 | Craig Ryan R | EVP & Chief HR Officer | tax withholding | 309 | $284.03 | $88K | 6,674 | Mar 4, 2026 |
| Mar 3, 2026 | Norwood Felicia F | EVP &Chief Health Benefits Ofr | tax withholding | 496 | $284.03 | $141K | 38,838 | Mar 4, 2026 |
| Mar 3, 2026 | Lavu Ratnakar | EVP & Chief Digital Info Ofr | tax withholding | 222 | $284.03 | $63K | 16,149 | Mar 4, 2026 |
| Mar 3, 2026 | Kendrick Charles Morgan JR | EVP & President, Commercial | tax withholding | 467 | $284.03 | $133K | 14,987 | Mar 4, 2026 |
| Mar 3, 2026 | Haytaian Peter D | EVP & Pres Carelon & CarelonRx | tax withholding | 446 | $284.03 | $127K | 27,222 | Mar 4, 2026 |
| Mar 3, 2026 | Kaye Mark | EVP & CFO | tax withholding | 353 | $284.03 | $100K | 32,037 | Mar 4, 2026 |
| Mar 3, 2026 | Boudreaux Gail | President and CEO, Director | tax withholding | 1,736 | $284.03 | $493K | 169,251 | Mar 4, 2026 |
| Mar 2, 2026 | Penczek Ronald W | CAO & Controller | tax withholding | 131 | $294.07 | $39K | 1,743 | Mar 4, 2026 |
| Mar 2, 2026 | Penczek Ronald W | CAO & Controller | award | 426 | $0.00 | — | 2,169 | Mar 4, 2026 |
Who the insiders are
Everyone who reported a transaction since November 1, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Kaye Mark | EVP & CFO | Oct 22, 2026 | open-market sale | 30,103 | — | $5M (13) | 0 of 13 |
| Boudreaux Gail | President and CEO, Director | Jul 17, 2026 | open-market buy | 169,931 | $1M (2) | — | — |
| Kendrick Charles Morgan JR | EVP & President, Commercial | Mar 6, 2026 | open-market sale | 11,791 | — | $911K (1) | 0 of 1 |
| Collis Steven H | Director | May 13, 2026 | award | 4,202 | $870K (1) | — | — |
| Penczek Ronald W | CAO & Controller | Jun 12, 2026 | open-market sale | 3,740 | — | $766K (2) | 0 of 2 |
| Peru Ramiro G | Director | Jul 17, 2026 | open-market buy | 10,908 | $366K (1) | — | — |
| Dixon Robert L JR | Director | Jun 11, 2026 | open-market sale | 10,734 | — | $61K (1) | 0 of 1 |
| Schulman Amy W | Director | May 13, 2026 | award | 781 | — | $7K (1) | 0 of 1 |
| Haytaian Peter D | EVP & Pres Carelon & CarelonRx | Mar 3, 2026 | tax withholding | 27,222 | — | — | — |
| Norwood Felicia F | EVP &Chief Health Benefits Ofr | Mar 3, 2026 | tax withholding | 38,838 | — | — | — |
| Wessling Erin M | EVP & Chief Legal Officer | Sep 3, 2026 | tax withholding | 7,230 | — | — | — |
| Craig Ryan R | EVP & Chief HR Officer | Sep 2, 2026 | tax withholding | 6,530 | — | — | — |
| Lavu Ratnakar | EVP & Chief Digital Info Ofr | Mar 3, 2026 | tax withholding | 16,149 | — | — | — |
| DeVore Susan D. | Director | May 13, 2026 | award | 4,065 | — | — | — |
| Strable-Soethout Deanna D | Director | May 13, 2026 | award | 2,209 | — | — | — |
| Schneider Ryan M. | Director | May 13, 2026 | award | 7,163 | — | — | — |
| Neri Antonio F | Director | May 13, 2026 | award | 5,488 | — | — | — |
| Jallal Bahija | Director | May 13, 2026 | award | 5,351 | — | — | — |
| Hay Lewis III | Director | May 13, 2026 | award | 12,070 | — | — | — |
| Clark R Kerry | Director | May 14, 2025 | award | 9,640 | — | — | — |
| Todt Blair Williams | EVP, CLO & CAO | Jan 3, 2025 | tax withholding | 15,631 | — | — | — |
Questions
Are Elevance Health, Inc. insiders buying or selling?
Over the twelve months to November 1, 2026, 5 insiders at Elevance Health, Inc. sold $6M of stock in the open market, all by officers and directors, and 3 insiders bought $2M, all by officers and directors. Net, insiders sold $4M. Only open-market purchases and sales are counted.
Who sold the most Elevance Health, Inc. stock in the last year?
Kaye Mark (EVP & CFO) sold $5M in 13 open-market sales over the twelve months to November 1, 2026.
Do Elevance Health, Inc. executives sell under 10b5-1 plans?
0 of the 18 open-market sales in the last twelve months (0%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Elevance Health, Inc.
- Elevance Health, Inc. financial statements
- 2 tracked funds holding ELV
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.